StockData

Syndax Pharmaceuticals vs Vanda Pharmaceuticals

SNDX and VNDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNDX and VNDA compare

Syndax Pharmaceuticals is the larger company, worth 3.6 times as much as Vanda Pharmaceuticals ($822M against $230M).

Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 8.1% for Vanda Pharmaceuticals).

Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −120% at Vanda Pharmaceuticals.

Vanda Pharmaceuticals scores higher on the StockData Score (10 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNDXVNDA
Size and price
Market cap$822M$230M
Share price$9.20$3.81
Change, 1 year−44.6%−12.4%
Change, 5 years−44.2%−77.0%
Beta (5Y)1.720.78
Employees298533
StockData Score
Total score310 (better)
Valuation score13 (better)
Growth score12 (better)
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S2.8×1.0× (better)
P/B–1.2×
FCF yield–−60.8%
Fair value–$8.53
Margin of safety–55.3%
Growth
Revenue growth (TTM)160% (better)8.1%
Revenue growth, 5Y average158% (better)−2.7%
Profitability
Gross margin–93.6%
Operating margin−61.7% (better)−77.6%
Net margin−72.3% (better)−120%
FCF margin–−61.0%
Return on equity−426%−82.5% (better)
Return on invested capital–−52.6%
Financial health
Debt / equity–0.00
Interest coverage−44660.0×–
Current ratio4.69 (better)1.54
Altman Z-score−2.30−1.85 (better)
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions121%82.2%
Held by insiders1.8%9.2%
Insider net buying, 12 months−$2.9M−$2.8M (better)
Short interest, % of float21.6%13.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.